VivoSeq
Oncology

Locally Advanced Colon Cancer

0

Pipeline Programs↗

13

Active Trials↗

0

Companies Involved↗

Locally Advanced Colon Cancer is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

8/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Unknown status8 · 32%
Not yet recruiting6 · 24%
Recruiting4 · 16%
Active, not recruiting3 · 12%
Terminated2 · 8%
Completed2 · 8%

Clinical Trials

Trial Activity

25 trials

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
Recruiting·FFudan University·Phase 3·NCT03125980·1,370 enrolled
HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer
Recruiting·—·Phase 2·NCT06709885·100 enrolled
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Recruiting·RRuijin Hospital·Phase 2·NCT06368141·56 enrolled
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Recruiting·XXiangya Hospital of Central South University·Phase 1/2·NCT03985891·40 enrolled
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Active, not recruiting·VVejle Hospital·Phase 3·NCT01918527·250 enrolled
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
Active, not recruiting·SSun Yat-sen University·Phase 3·NCT02572141·738 enrolled
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Active, not recruiting·KKyungpook National University Hospital·Phase 3·NCT03426904·708 enrolled
MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06890624·138 enrolled
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06790212·168 enrolled
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT07132008·94 enrolled
Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study
Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06594692·140 enrolled
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer
Not yet recruiting·MMaimónides Biomedical Research Institute of Córdoba·Phase 3·NCT06783491·1,083 enrolled
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Not yet recruiting·SSun Yat-sen University·N/A·NCT07413146·100 enrolled
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Completed·ZZhejiang University·Phase 2·NCT04625803·64 enrolled
Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study
Completed·National Cancer Institute, Naples·Phase 2·NCT04123925·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)